The OTC Markets Group Inc (OTCQX: OTCM) announced Wednesday that Canntab Therapeutics Limited (CSE:PILL) (OTQX: CTABF), has qualified to trade on the best market, having been upgraded from the OTCQB venture
Canntab Therapeutics, based in Markham, Ontario, specializes in the research and development of pharmaceutical-grade formulations of cannabinoids.
"Canntab Therapeutics joins the OTCQX best market, trading alongside over 45 other cannabis companies that are innovators in the industry," said Jason Paltrowitz, executive vice president of corporate services at the OTC Markets Group. "Cross-trading on OTCQX provides Canntab Therapeutics' US investors with greater access to the company's financials, news and research reports. We look forward to supporting Canntab Therapeutics as it expands its footprint in the US."
Canntab Therapeutics has 13 patents pending in the US and Canada. The company’s oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract. This includes extended-release, flash melt, immediate release, modified release and bi-layered tablets.
The company is the first to offer medical cannabis in pill form and its suite of products continues to grow. The tablets are intended to treat a variety of disorders including post-traumatic stress disorder and arthritis and can also act as a pain management and appetite loss drug for patients undergoing cancer treatments
"Historically, it's been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX best market,” said Canntab Therapeutics' chief financial officer Richard Goldstein. “This move also coincides with Canntab reaching a major milestone in April, which has opened the door for Canadian and international sales and white labeling."
Hard pill oral dosage
Canntab's goal is to become a global leader of research in hard pill oral dosage therapeutic cannabis.
"Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary process," said Canntab Therapeutics CEO Jeff Renwick.
Contact Uttara Choudhury at [email protected]